$83.8462
-2.6638[-3.08%]
At close: Apr 22
$83.8462
0[0.00%]
PreMarket: 6:28PM EDT
TransMedics Gr
(NASDAQ:TMDX)TransMedics Gr Stock (NASDAQ:TMDX), Analyst Ratings, Price Targets, Predictions
TransMedics Group Inc has a consensus price target of $71.91, established from looking at the 32 latest analyst ratings. The last 3 analyst ratings were released from Piper Sandler, Morgan Stanley, and JP Morgan on March 28, 2024, February 28, 2024, and February 27, 2024. With an average price target of $98.33 between Piper Sandler, Morgan Stanley, and JP Morgan, there's an implied 17.28% upside for TransMedics Group Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
Morgan Stanley
JP Morgan
Oppenheimer
JP Morgan
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for TransMedics Gr
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/28/2024 | TMDX | Buy Now | TransMedics Gr | $83.85 | 13.3% | Piper Sandler | Matt O'Brien | → $95 | Initiates | → Overweight | Get Alert |
| 02/28/2024 | TMDX | Buy Now | TransMedics Gr | $83.85 | 13.3% | Morgan Stanley | Cecilia Furlong | $75 → $95 | Maintains | Equal-Weight | Get Alert |
| 02/27/2024 | TMDX | Buy Now | TransMedics Gr | $83.85 | 25.23% | JP Morgan | Allen Gong | $87 → $105 | Maintains | Overweight | Get Alert |
| 02/27/2024 | TMDX | Buy Now | TransMedics Gr | $83.85 | 25.23% | Oppenheimer | Suraj Kalia | $92 → $105 | Maintains | Outperform | Get Alert |
| 12/04/2023 | TMDX | Buy Now | TransMedics Gr | $83.85 | -10.55% | Morgan Stanley | Cecilia Furlong | $54 → $75 | Maintains | Equal-Weight | Get Alert |
| 11/07/2023 | TMDX | Buy Now | TransMedics Gr | $83.85 | -16.51% | JP Morgan | Thomas Allen | $67 → $70 | Maintains | Overweight | Get Alert |
| 11/07/2023 | TMDX | Buy Now | TransMedics Gr | $83.85 | -35.6% | Morgan Stanley | Cecilia Furlong | $50 → $54 | Maintains | Equal-Weight | Get Alert |
| 10/13/2023 | TMDX | Buy Now | TransMedics Gr | $83.85 | -40.37% | Morgan Stanley | Cecilia Furlong | $81 → $50 | Maintains | Equal-Weight | Get Alert |
| 08/04/2023 | TMDX | Buy Now | TransMedics Gr | $83.85 | 31.19% | TD Cowen | Joshua Jennings | $95 → $110 | Maintains | Outperform | Get Alert |
| 07/19/2023 | TMDX | Buy Now | TransMedics Gr | $83.85 | — | William Blair | — | — | Initiates | → Outperform | Get Alert |
| 05/18/2023 | TMDX | Buy Now | TransMedics Gr | $83.85 | 2.57% | Canaccord Genuity | William Plovanic | $91 → $86 | Maintains | Buy | Get Alert |
| 05/03/2023 | TMDX | Buy Now | TransMedics Gr | $83.85 | -3.39% | Morgan Stanley | Cecilia Furlong | $74 → $81 | Maintains | Equal-Weight | Get Alert |
| 05/02/2023 | TMDX | Buy Now | TransMedics Gr | $83.85 | 7.34% | Oppenheimer | Suraj Kalia | $85 → $90 | Maintains | Outperform | Get Alert |
| 02/23/2023 | TMDX | Buy Now | TransMedics Gr | $83.85 | -10.55% | Cowen & Co. | Joshua Jennings | $70 → $75 | Maintains | Outperform | Get Alert |
| 02/23/2023 | TMDX | Buy Now | TransMedics Gr | $83.85 | -6.97% | Canaccord Genuity | William Plovanic | $68 → $78 | Maintains | Buy | Get Alert |
| 02/23/2023 | TMDX | Buy Now | TransMedics Gr | $83.85 | -3.39% | JP Morgan | Thomas Allen | $67 → $81 | Maintains | Overweight | Get Alert |
| 02/23/2023 | TMDX | Buy Now | TransMedics Gr | $83.85 | 1.38% | Oppenheimer | Suraj Kalia | $55 → $85 | Maintains | Outperform | Get Alert |
| 02/23/2023 | TMDX | Buy Now | TransMedics Gr | $83.85 | -11.74% | Morgan Stanley | Cecilia Furlong | $63 → $74 | Maintains | Equal-Weight | Get Alert |
| 01/06/2023 | TMDX | Buy Now | TransMedics Gr | $83.85 | -24.86% | Morgan Stanley | Cecilia Furlong | $54 → $63 | Maintains | Equal-Weight | Get Alert |
FAQ
What is the target price for TransMedics Gr (TMDX)?
The latest price target for TransMedics Gr (NASDAQ: TMDX) was reported by Piper Sandler on March 28, 2024. The analyst firm set a price target for $95.00 expecting TMDX to rise to within 12 months (a possible 13.30% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for TransMedics Gr (TMDX)?
The latest analyst rating for TransMedics Gr (NASDAQ: TMDX) was provided by Piper Sandler, and TransMedics Gr initiated their overweight rating.
When was the last upgrade for TransMedics Gr (TMDX)?
The last upgrade for TransMedics Group Inc happened on August 2, 2022 when JP Morgan raised their price target to $48. JP Morgan previously had a neutral for TransMedics Group Inc.
When was the last downgrade for TransMedics Gr (TMDX)?
There is no last downgrade for TransMedics Gr.
When is the next analyst rating going to be posted or updated for TransMedics Gr (TMDX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TransMedics Gr, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TransMedics Gr was filed on March 28, 2024 so you should expect the next rating to be made available sometime around March 28, 2025.
Is the Analyst Rating TransMedics Gr (TMDX) correct?
While ratings are subjective and will change, the latest TransMedics Gr (TMDX) rating was a initiated with a price target of $0.00 to $95.00. The current price TransMedics Gr (TMDX) is trading at is $83.85, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.